Ken Kato, National Cancer Center Hospital, Japan
How liquid biopsy is revolutionizing efficacy evaluation and treatment strategies in esophageal cancer, with insights into his lead international Phase III trial tracking minimal residual disease via ctDNA and other novel technologies.